【can you use wd40 to clean a carb】AstraZeneca's (AZN) Lung Cancer Drug Gets Full FDA Approval
AstraZeneca plc
AZN announced that its lung cancer drug,can you use wd40 to clean a carb Tagrisso has received full approval from the FDA.
We remind investors that Tagrisso had earlier received accelerated approval in 2015. The approval of the drug will help it to become a standard for the treatment of EGFR T790M mutation-positive, locally-advanced or metastatic non-small cell lung cancer (NSCLC) in adults, whose disease had progressed following first-line EGFR tyrosine kinase inhibitor (TKI) therapy.
Tagrisso, a third generation, irreversible EGFR inhibitor, is now available in more than 45 countries across the globe including the U.S., EU, Japan and China. Tagrisso is now the only approved drug available in the U.S. for NSCLC patients with EGFR T790 mutation.
Shares of AstraZeneca have risen 14% since the beginning of this year, outperforming the Zacks classified Large Cap Pharmaceuticals industry, which increased 6% in the same period.
Full approval of the drug is based on positive data from the phase III study AURA3 trial
Data from the study demonstrated statistically-significant improvement in progression-free survival (PFS) compared to standard platinum-based doublet chemotherapy. The data showed that treatment with Tagrisso reduced risk of disease progression by 70% and improved median progression-free survival (PFS) by 10.1 months compared to of 4.4 months in patients treated with platinum-based doublet chemotherapy.
The trial results were presented at the 17th World Conference on Lung Cancer.
The drug is designed to stop the mutation in virus and prevent it from becoming treatment resistant. Patients are treated with Tagrisso only if they are diagnosed with EGFR T790M mutation in the tumor. Meanwhile, Tagrisso is also being investigated for the treatment of adjuvant and metatstatic first line settings patients, with and without brain metastases. It is also being tested for the treatment of leptomeningeal disease and as combination therapies.
According to the data presented in the press release, lung cancer is a major cause of deaths due to cancer in both men and women. As per the numbers, 15-20% of the patients in the U.S. and Europe with NSCLC are diagnosed with EGFR mutation and approximately two-thirds of these patients develop T790 mutation after initial EGFR TKI therapy.
We are encouraged by the full approval of Tagrisso in the U.S. Uptake of the drug among patients worldwide is increasing steadily. Tagrisso earned revenues of $423 million worldwide in 2016. In the fourth quarter of 2016, the drug recorded sales of $147 million, increasing 10.5% sequentially.
Story continues
We remind investors that Roche Holding AG RHHBY had developed a diagnostic test to identify NSCLC patients with a T790M mutation and are eligible for treatment with Tagrisso. The test was approved by the FDA in Nov 2015.
Zacks Rank & Picks
AstraZeneca carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the health care sector include Vertex Pharmaceuticals Incorporated VRTX and Corvus Pharmaceuticals, Inc. CRVS. Corvus sports a Zacks Rank #1 (Strong Buy) while Vertex carries a Zacks Rank #2 (Buy). You can see
the complete list of today’s Zacks #1 Rank stocks here.
Shares of Vertex have risen 48.4% this year so far while earnings estimates for 2017 have gone up by almost 4% in the past 30 days.
Corvus’ loss estimates narrowed from $3.64 to $3.35 for 2017 over the last 60 days. Shares of the company have risen 45.4% since the beginning of this year.
More Stock News: 8 Companies Verge on Apple-Like Run
Did you miss Apple's 9X stock explosion after they launched their iPhone in 2007? Now 2017 looks to be a pivotal year to get in on another emerging technology expected to rock the market. Demand could soar from almost nothing to $42 billion by 2025. Reports suggest it could save 10 million lives per decade which could in turn save $200 billion in U.S. healthcare costs.
A bonus Zacks Special Report names this breakthrough and the 8 best stocks to exploit it. Like Apple in 2007, these companies are already strong and coiling for potential mega-gains.
Click to see them right now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.
Click to get this free report
Roche Holding AG (RHHBY): Free Stock Analysis Report
Astrazeneca PLC (AZN): Free Stock Analysis Report
Vertex Pharmaceuticals Incorporated (VRTX): Free Stock Analysis Report
Corvus Pharmaceuticals, Inc. (CRVS): Free Stock Analysis Report
To read this article on Zacks.com click here.
View comments
-
The New America High Income Fund, Inc. Declares DividendHow to Time the Markets Like an Investing Pro - April 01, 2020Tembo Gold Adds 70 km2 Adjoining Bulyanhulu and Provides Prospecting Licence UpdateMike Bloomberg thinks a gun-control pitch works … in TexasGBP/USD Price Forecast – British Pound Charging Into Big Figure AgainRamping up COVID-19 testing earlier would have helped the UK, top adviser saysHere's How Long It Took Apple To Reach A $100B Market CapIs Focus Financial Partners (FOCS) a Great Growth Stock?George Floyd protests recall earlier tensions, promises of economic changeHarpoon Therapeutics Reports Third Quarter 2020 Financial Results and Provides Corporate Update
下一篇:35 Surprising Cities With Low Costs of Living
- ·Why Uranium Markets Are Gaining Interest
- ·Smithfield Foods Says That the Company and Its Team Members Want the Same Thing: To Protect Employee Health and Safety While Also Safeguarding America’s Food Supply
- ·Hedge Funds Aren’t Done Buying Euronav NV (EURN)
- ·Coronavirus fears spark 'panic buying' of toilet paper, water, hand sanitizer. Here's why we all need to calm down
- ·Lockheed Martin (LMT) Wins $1B Deal for Super Hercules Fleet
- ·Sun Summit Minerals Phase 2 Drilling Update and Completion of IP Survey at the Buck Property
- ·Should Value Investors Buy Avis Budget Group (CAR) Stock?
- ·Recap: eXp World Holdings Q1 Earnings
- ·EUR/USD Bullish Break Kick Starts Reversal to 1.13?
- ·Exclusive: U.S. sanctions have idled a quarter of Iranian oil rigs
- ·Natural Gas Price Fundamental Daily Forecast – Crushed by ‘Exceptionally Comfortable’ Temps Ahead of EIA Data
- ·Growth Stocks To See 'Nirvana' With Blue White House, Divided Congress, Cramer Says
- ·Apple's New Deal With Amazon Prime Video Is a Game Changer
- ·A village of tiny Victorian homes offers a life-changing experience
- ·George Floyd protests recall earlier tensions, promises of economic change
- ·Blockchain Industries Appoints New Board Members
- ·Meritor to Cut Global Salaried Workers on Coronavirus Scare
- ·Paycheck Protection Program (PPP) Loans
- ·Before You Buy Youngevity International, Inc. (NASDAQ:YGYI), Consider Its Volatility
- ·Stifel Financial Appoints Kathleen Brown Lead Independent Director
- ·Were Hedge Funds Wrong About Crowding Into RealPage, Inc. (RP)?
- ·Trump calls for shift in coronavirus strategy to allow for end to lockdowns
- ·How to Time the Markets Like an Investing Pro - April 01, 2020
- ·Genco Shipping & Trading (GNK) Lags Q3 Earnings and Revenue Estimates
- ·JPMorgan Increases Stake in China Securities Venture to 71%
- ·Spa chain secured $5.6M in coronavirus relief for small businesses despite losses last year
- ·Pinduoduo’s AI strawberry competition offers glimpse of “one-click planting”
- ·Analysts Estimate Stitch Fix (SFIX) to Report a Decline in Earnings: What to Look Out for
- ·Is The Goldman Sachs Group (GS) Stock Outpacing Its Finance Peers This Year?
- ·Retail sector companies turn to masks, gloves in coronavirus fight
- ·Why the Earnings Surprise Streak Could Continue for Dick's (DKS)
- ·India gold discounts at widest in five months as prices surge
- ·What Is MDU Resources Group's (NYSE:MDU) P/E Ratio After Its Share Price Tanked?
- ·Manganese X Receives Eligibility for DTC Trading in the U.S.
- ·Has TerraForm Power (TERP) Outpaced Other Utilities Stocks This Year?
- ·INVESTOR APRIL DEADLINE REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Aaron's, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm